Capricor Therapeutics, Inc.

Thank you. We'll be right back.

Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics First Quarter 2026 Conference Call. At this time, all participant lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Tuesday, May 12, 2026. I would now like to turn the conference over to our CFO, AJ Bergman, for the forward-looking statement. Please go ahead.

Thank you, and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, potential regulatory developments involving our product candidates, our future R&D plans, our anticipated conduct and timing of preclinical and clinical studies, enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory inspections, revenue and reimbursement estimates, projected terms of definitive agreements, manufacturing capabilities, our financial position, our possible uses of existing cash and investment resources, and statements regarding our litigation with Nippon Shin'yaku and NS Pharma Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize DERMA-ISL independent of our existing distribution agreements. These forward-looking statements are based on our current information assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings with the SEC, including our quarterly and annual reports. We are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements. With that, I'll turn the call over to Linda Marvan, CDO.